Bio Green Med Solution (BGMS)
NASDAQ:BGMS
Top Page
Bio Green Med Solution
(NASDAQ:BGMS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.99
▼(-31.72% Downside)
Action:ReiteratedDate:04/05/26
BGMS scores low primarily due to persistent losses and continued negative operating/free cash flow despite improved 2025 revenue and low debt. Technicals remain weak on a longer-term basis (below key moving averages), while valuation is mixed (high dividend yield but negative P/E). Corporate events are balanced by operational transition progress offset by the preferred-share delisting.
Positive Factors
Revenue rebound and early commercialization
A 2025 revenue rebound from $0.04M to $0.75M signals initial commercial traction after the strategic pivot. Sustained top-line growth from a new product mix can compound, enabling scale benefits that improve gross margins and reduce reliance on external capital over the medium term.
Negative Factors
Persistent negative operating and free cash flow
Operating and free cash flow remain materially negative (-$4.77M in 2025), showing the company still consumes cash despite improvements. Persistent negative cash generation forces continued reliance on external financing or dilution and constrains the ability to invest in scaling operations sustainably over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound and early commercialization
A 2025 revenue rebound from $0.04M to $0.75M signals initial commercial traction after the strategic pivot. Sustained top-line growth from a new product mix can compound, enabling scale benefits that improve gross margins and reduce reliance on external capital over the medium term.
Read all positive factors
Bio Green Med Solution (BGMS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.57M
Dividend Yield10.27%
Average Volume (3M)473.94K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth9.46%
EPS Growth96.85%
CountryUS
Employees12
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-2.21
Shares Outstanding5,519,456
10 Day Avg. Volume1,252,948
30 Day Avg. Volume473,939
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.47
Price to Sales (P/S)4.33
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.23
Enterprise Value/Revenue-1.74
Enterprise Value/Gross Profit-9.49
Enterprise Value/Ebitda0.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-268.8
Revenue Forecast (FY)$100.00K
Bio Green Med Solution Business Overview & Revenue Model
Company Description
A diversified company operating in both the fire protection and biopharmaceutical industries. It expanded its portfolio by acquiring Fitters Sdn. Bhd., a Malaysian fire protection products and services group. Focuses on advancing opportunities in ...
Bio Green Med Solution Earnings Call Summary
Earnings Call Date:Aug 14, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The earnings call reflects a positive outlook with significant progress in the clinical development of fadra and a strong financial position, despite some challenges in R&D tax credits and increased expenses for topogezotitib.Positive Updates
Progress in Fadra Phase II Study
Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.
Negative Updates
Decrease in R&D Tax Credits
UK research and development tax credits decreased significantly to $0.4 million for Q2 2024, compared to $6 million for the same period in the previous year.
Read all updates
Q2-2024 Updates
Positive
Negative
Progress in Fadra Phase II Study
Cyclacel reported successful recruitment in the enriched cohort of their Phase II proof-of-concept study for fadra, with positive preliminary signals in heavily pretreated patients across various cancer types. Initial clinical activity is expected to be reported in Q4 2024.
Read all positive updates
Company Guidance
During the Cyclacel Q2 2024 earnings call, the company provided key updates on their precision medicine strategy, particularly focusing on fadra, an oral CDK2/9 inhibitor. Recruitment is progressing well in the 065-101 Phase II proof-of-concept study, with an enriched cohort targeting patients with CDKN2A and CDK NIB chromosomal abnormalities. Initial clinical activity results are expected in Q4 2024. Financially, Cyclacel reported cash equivalents of $6 million as of June 2024, with net cash used in operating activities amounting to $3.6 million for the first half of the year, indicating a decrease from $8.2 million in the same period of 2023. Research and development expenses for the quarter were $2 million, a reduction from $4.7 million in Q2 2023, with specific R&D expenses for fadra at $1.5 million, down from $3 million the previous year. The company anticipates that current cash resources will cover planned programs into the fourth quarter of 2024.Bio Green Med Solution Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 747.00K | 43.00K | 420.00K | 0.00 | 0.00 |
| Gross Profit | 138.00K | 43.00K | 420.00K | 0.00 | 0.00 |
| EBITDA | -8.42M | -12.00M | -25.42M | -27.62M | -22.35M |
| Net Income | -3.00M | -11.21M | -22.55M | -21.20M | -18.46M |
Balance Sheet | |||||
| Total Assets | 8.19M | 4.09M | 8.80M | 28.05M | 43.14M |
| Cash, Cash Equivalents and Short-Term Investments | 3.50M | 3.14M | 3.38M | 18.34M | 36.56M |
| Total Debt | 2.00K | 0.00 | 37.00K | 106.00K | 30.00K |
| Total Liabilities | 1.34M | 6.27M | 8.20M | 7.62M | 5.44M |
| Stockholders Equity | 6.84M | -2.17M | 607.00K | 20.43M | 37.69M |
Cash Flow | |||||
| Free Cash Flow | -4.77M | -7.99M | -16.12M | -20.83M | -18.57M |
| Operating Cash Flow | -4.77M | -7.99M | -16.11M | -20.83M | -18.54M |
| Investing Cash Flow | 0.00 | 0.00 | -6.00K | -7.00K | -27.00K |
| Financing Cash Flow | 5.26M | 7.82M | 848.00K | 3.00M | 21.74M |
Bio Green Med Solution Technical Analysis
Positive
1.45
Price Trends
0.99
Positive
1.21
Negative
3.67
Negative
Market Momentum
<0.01
Negative
51.54
Neutral
59.72
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BGMS, the sentiment is Positive. The current price of 1.45 is above the 20-day moving average (MA) of 0.97, above the 50-day MA of 0.99, and below the 200-day MA of 3.67, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.54 is Neutral, neither overbought nor oversold. The STOCH value of 59.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BGMS.
Bio Green Med Solution Risk Analysis
Bio Green Med Solution disclosed 71 risk factors in its most recent earnings report. Bio Green Med Solution reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio Green Med Solution Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $25.77M | 2.36 | -1538.29% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $41.78M | -0.59 | -281.00% | ― | ― | 15.35% | |
47 Neutral | $5.57M | -1.08 | -226.28% | 10.27% | 9.46% | 96.85% | |
44 Neutral | $1.73M | -0.18 | -145.52% | ― | ― | 97.70% | |
43 Neutral | $1.52M | -0.19 | -63.03% | ― | -100.00% | 86.75% |
* Healthcare Sector Average
BGMS
Bio Green Med Solution
1.01
-56.35
-98.24%
BDRX
Biodexa Pharmaceuticals
3.36
-85.14
-96.20%
RNTX
Rein Therapeutics
1.49
-0.22
-12.87%
BJDX
Bluejay Diagnostics
1.78
-8.78
-83.14%
NEUP
Neuphoria Therapeutics
4.78
-0.17
-3.43%
Bio Green Med Solution Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Bio Green Med Highlights 2025 Transition and Improved Results
Positive
Mar 30, 2026
Bio Green Med Solution, Inc., now focused on fire safety protection and distribution after exiting its legacy biopharmaceutical activities, reported that the September 12, 2025 acquisition of Fitters Sdn. Bhd. generated $0.7 million in fire safety...
Delistings and Listing ChangesRegulatory Filings and Compliance
Bio Green Med Preferred Shares Set for Nasdaq Delisting
Negative
Mar 13, 2026
Bio Green Med Solution, Inc. disclosed that on September 11, 2025 it was notified by Nasdaq that its 6% Convertible Exchangeable Preferred Stock, trading under the symbol BGMSP, had failed for 30 consecutive business days to meet the $1 million mi...
Dividends
Bio Green Med Solution Declares Quarterly Preferred Stock Dividend
Positive
Jan 12, 2026
On January 12, 2026, Bio Green Med Solution, Inc. announced that its board of directors declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Preferred Stock, payable on February 1, 2026, to holders of record as ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.